Preclinical development of AMG 139, a human antibody specifically targeting IL-23

Protective Immunity to Systemic Infection with Attenuated Salmonella enterica serovar Enteritidis in the Absence of IL-12 Is Associated with IL-23-Dependent IL-22, but Not IL-17

(2014) S. M. Schulz et al.   JOURNAL OF IMMUNOLOGY

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors

(2013) Stephen P.H. Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Concise Guide to PHARMACOLOGY 2013/14: Overview

(2013) Stephen P.H. Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Pharmacology of AMG 181, a human anti-α4β7antibody that specifically alters trafficking of gut-homing T cells

(2013) WJ Pan et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study

(2013) K.A. Papp et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Antibodies to watch in 2013

(2013) Janice M Reichert   mAbs

The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands

(2013) Adam J. Pawson et al.   NUCLEIC ACIDS RESEARCH

Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility Loci

(2012) David Ellinghaus et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State

(2012) Michele W. L. Teng et al.   CANCER RESEARCH

Interleukin-12: Clinical usage and molecular markers of cancer susceptibility

(2012) Arseniy E. Yuzhalin et al.   GROWTH FACTORS

Association of IL23R polymorphisms with psoriasis and psoriatic arthritis: a meta-analysis

(2012) Kun-Ju Zhu et al.   INFLAMMATION RESEARCH

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

(2012) A.B. Kimball et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials

(2012) T. Tzellos et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

A strategy for risk mitigation of antibodies with fast clearance

(2012) Isidro Hötzel et al.   mAbs

Associations between interleukin-23 receptor polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis

(2012) Gwan Gyu Song et al.   MOLECULAR BIOLOGY REPORTS

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Decreased Plasma IL-35 Levels Are Related to the Left Ventricular Ejection Fraction in Coronary Artery Diseases

(2012) Yingzhong Lin et al.   PLoS One

Briakinumab for the Treatment of Plaque Psoriasis

(2011) Pawel Traczewski et al.   BIODRUGS

Quantitative Prediction of Human Pharmacokinetics for Monoclonal Antibodies

(2011) Jennifer Q. Dong et al.   CLINICAL PHARMACOKINETICS

IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease

(2011) Alessandra Geremia et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis

(2011) Kenneth B. Gordon et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice

(2011) J H Cox et al.   Mucosal Immunology

A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis

(2011) Kristian Reich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for reporting experiments involving animals: the ARRIVE guidelines

(2010) JC McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Nathanael L. Dirks et al.   CLINICAL PHARMACOKINETICS

Circulating levels of interleukin-17A and interleukin-23 are increased in patients with gonococcal infection

(2010) Maria Cristina Gagliardi et al.   FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY

Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters

(2010) Manjula REDDY et al.   JOURNAL OF DERMATOLOGY

IL-1RL2 and Its Ligands Contribute to the Cytokine Network in Psoriasis

(2010) H. Blumberg et al.   JOURNAL OF IMMUNOLOGY

Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology

(2010) Sofia Buonocore et al.   NATURE

Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis

(2010) E. Nogueira et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis

(2010) M. W. L. Teng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis

(2009) L. van der Fits et al.   JOURNAL OF IMMUNOLOGY

High-affinity binding measurements of antibodies to cell-surface-expressed antigens

(2007) Palaniswami Rathanaswami et al.   ANALYTICAL BIOCHEMISTRY